Related Experiment Video
Updated: Feb 3, 2026

Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
Nonaspirin NSAIDs and contralateral breast cancer risk
Annet Bens1, Deirdre Cronin-Fenton2, Christian Dehlendorff3
1Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Abstract:
Laboratory studies suggest that inhibition of the cyclooxygenase (COX)-2 enzymes inhibits breast cancer development. We aimed to evaluate whether postdiagnosis use of COX-2 selective or other nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of contralateral breast cancer (CBC) among Danish breast cancer patients. From the clinical database of the Danish Breast Cancer Group, we identified 52,723 women diagnosed with breast cancer between 1996 and 2012. Data on nonaspirin NSAID use, CBC and potential confounding variables were obtained from nationwide registries. We defined postdiagnosis use (two or more prescriptions) as a time-varying covariate with a one-year lag. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CBC associated with nonaspirin NSAID use. During a median follow-up of 4.8 years (interquartile range: 2.3-9 years), 1,444 patients were diagnosed with CBC. Overall, postdiagnosis use of nonaspirin NSAID was associated with an adjusted HR for CBC of 0.98 (95% CI: 0.87-1.11). The HRs did not vary substantially with duration or intensity of nonaspirin NSAID use. Moreover, similar associations were found for COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs. In conclusion, our nationwide cohort study of breast cancer patients does not suggest a reduced risk of CBC with nonaspirin NSAID use regardless of the COX-2 selectivity.
Insights
Postdiagnosis use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) did not reduce the risk of contralateral breast cancer (CBC) in Danish patients. This finding applies regardless of whether the NSAIDs were cyclooxygenase (COX)-2 selective or nonselective.
Area of Science:
- Oncology
- Pharmacology
Background:
- Laboratory studies indicate cyclooxygenase (COX)-2 inhibition may suppress breast cancer development.
- Nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) include COX-2 selective and nonselective agents.
Purpose of the Study:
- To investigate if postdiagnosis use of nonaspirin NSAIDs impacts contralateral breast cancer (CBC) risk in Danish breast cancer patients.
- To differentiate the effects of COX-2 selective versus nonselective NSAIDs on CBC risk.
Main Methods:
- A nationwide cohort study of 52,723 Danish breast cancer patients diagnosed between 1996 and 2012.
- Utilized nationwide registries for data on NSAID use, CBC diagnosis, and confounding variables.
- Employed Cox proportional hazard regression models to analyze the association between postdiagnosis NSAID use and CBC risk, with a one-year lag.
Main Results:
- Overall postdiagnosis nonaspirin NSAID use showed an adjusted hazard ratio (HR) of 0.98 (95% CI: 0.87-1.11) for CBC.
- No substantial variation in HRs was observed with NSAID use duration or intensity.
- Both COX-2 selective (HR: 1.02; 95% CI: 0.85-1.23) and nonselective (HR: 0.96; 95% CI: 0.82-1.13) nonaspirin NSAIDs demonstrated similar non-significant associations with CBC risk.
Conclusions:
- This nationwide cohort study suggests that postdiagnosis use of nonaspirin NSAIDs does not reduce the risk of contralateral breast cancer.
- The findings indicate no significant difference in CBC risk reduction between COX-2 selective and nonselective nonaspirin NSAIDs.
Related Concept Videos
Relative Risk
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Design Example: Analyzing Capacity Contours for Flood Risk Assessment
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

